CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo
The CRISPR-Cas13a gene-editing system has been demonstrated to significantly suppress tumor proliferation both in vitro and in vivo, thereby presenting itself as a promising candidate for a novel and efficacious therapeutic intervention in bladder cancer treatment.
Authors
- Shangwen Liu
- Yuchen Liu (ORCID: https://orcid.org/0000-0001-8922-9976)
- Mianxiong Chen
- Dakun Huang
- Yibin Wang (ORCID: https://orcid.org/0000-0003-0852-0767)
- Guibiao Wen
- Zhengbo Sun (ORCID: https://orcid.org/0000-0001-7497-3516)
- Lin Feng (ORCID: https://orcid.org/0000-0003-0981-031X)
- Jinjin Zhu
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Shenzhen Institutes of Advanced Technology (CN)
- Shenzhen Second People's Hospital (CN)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/ott.s492659
- Citations
- 2
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.47